Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Definitely agree.
I would love to see 3M take a run at this.
I do agree that those of us that have hung on 2 plus years are stuck and really can’t see them selling.
For example, if you bought at $0.10 and didn’t sell through the previous highs(remember 2019 at $2) then why sell now.
And if you bought at $0.70++ that’s just too big of a loss when there is such a good chance of it going beyond those levels.
However, 2022 has been a year in the 0.50s pps and below so I could certainly see a scenario where new 2022 investors are just saying “enough of this uncertainty “ and walking away.
The new pressure on peoples mortgages, lines of credit and just access to cash is enough to cause panic.
That’s not Thom’s Direct line. Simply an info / contact all purpose line for customers etc. listed on UHPs contact page.
This Phone Line is out of Connecticut.
The PO Box is in NV.
Thom works out of NY.
Many layers to this onion.
Looks like Philippe used just vague enough wording to trick you one more time before he goes.
UHP site.
Corporate Headquarters
526 Commerce Circle, Suite 120
Mesquite, NV 89027
Investor & Commercial Contact
info@unitedhealthproductsinc.com
475.755.1005 (phone or text)
If Fred Flintstone wasn’t allowed to moonlight from the rock quarry then neither should Thom.
Mr. Slate would be furious.
Did your research show that he still holds the title of Managing Director at Oberon Securities? Personally, I’m just hoping he’s giving UHP the focus it deserves and is proud to be associated with the company.
His personal online profiles like LinkedIn don’t seem to mention UHP. I’m not a LinkedIn user so i could be wrong - doubtful.
I believe he thought PMA was a slam dunk when he came on board and he’d focus on his specialty of Mergers and Acquisitions. Unfortunately, he like many others, found out this wasn’t the case.
One day I suppose I’ll be wrong, but this isn’t it :) see below.
I agree with your earlier post though. The FDA has no issue with companies sharing clear and accurate updates. Plus, The SEC encourages it.
————
Fall ends Dec 21st.
Lonetree
“Wave, long time ago you predicted action from FDA in the fall. If memory is correct. Are you still on that thought?”
Waverunner
“Definitely.
But UHP has lots work to do for that “action” to be positive.”
Are you able to share what the FDA and SEC discovered based on false accusations forwarded July 25th.
Access to $11 million should help.
Hopefully, they didn’t have to agree to sell the $10M too cheap. But at this point they have to do what’s necessary.
Note, the following does not mean market value:
“Any common stock sold to White Lion will occur at a purchase price derived from the prevailing market prices of the company’s common stock at the time of each sale.”
Likely pps will be something like:
market price - 10% , with max price of 0.35 per share.
It remains the same since the day they moved out of China:
Today’s PR:
“… establishment and inspection of gauze production, drafting of associated documentation, and testing of product to ensure conformance with previous product specifications
March 2022:
“There is nothing the FDA can do until UHP can prove capable of producing hemostyp gauze in the new facility exactly as they used in the human trials. “
Definitely.
But UHP has lots work to do for that “action” to be positive.
More importantly, did the FDA and SEC follow up on the emails you sent them. Did they agree with your accusations? Is there a major investigation into UHP going on right now? How many government agencies are involved?
Quote:
“Was all of this the plan from Johnson & Johnson all along? Did they provide the wolf in sheep's clothing, hoping to stymie UEEC's approval and pick up the assets on the cheap? Why did Brian Thom hire this guy to begin with?
Copies being sent to FDA OIG.
SEC / FINRA
If this was the plan, this post marks the beginning of the end for those in cahoots. I can promise you all that.”
Explain this post please. In what possible scenario would a short need to dump ueec shares to cover?
Refresher post on how shorting works.
Readers, you do understand that he has accused our CEO of corruption and deliberately causing shareholders harm.
This on the heals of the SEC fining our former CEO for fraud.
He also claims to have now sent this information to the FDA and SEC
With no evidence other than a if/maybe/…..
What kind of delays would this cause and absolute bottoming out of pps.
“So not Thom really screwed up” but “Thom deliberately schemed against his own shareholders.”
The only reason Shorts would be “dumping” hundreds of thousands of shares is if they’re predicting they can buy them back in the future at a much lower price. So that wouldn’t be good.
Hence, would a Short not be the one purchasing the shares in order to return them to the original lender?
For example, when the stock went to 0.80 May 13th and demand was unreasonably high, a Short would have borrowed and sold. And now when shares have dropped to 0.40s they buy back and return. Making a $0.3++ return per share.
I typically don’t wade into these shorts/MM debates as they seem to be a common dialog every time the stock goes down, but are never mentioned when the stock goes up.
Now, seeing that I admit to not being an absolute expert on these matters I will finish with the famous JMO.
There is of course the possibility that Perhaps the pps is exactly where the market has naturally taken it.
JMO
First of all, good for UHP for making the donation. That’s awesome.
However, This was not new product. DD below laid out in a fashion much easier to follow below.
Apr 1st 2022
“ In an effort to support the people of Ukraine and those working to defend the country against the Russian invasion, UHP is donating 10,000 units of its HemoStyp hemostatic gauze”
April 1 equipment:
The company notes that its manufacturing equipment remains in good operational condition and is on location at the premises of our FDA-approved contract manufacturing partner. The equipment is ready to become operational in anticipation of an FDA inspection and/or the need to produce HemoStyp material for commercial orders.
April 1 inventory:
in consultation with its auditors, has written off the value of its production equipment and certain work-in-progress inventory due to the extended period of inactivity,
I agree. Doubt they will fire him though. How many shares did UHP pay him?
One of the most overused phrases in UHP PRs has been:
“The FDA has asked for no further information at this time”
Leading readers to believe that everything is complete and next step is the final decision.
However, just because they have submitted information doesn’t mean that information is to FDA standards, or in agreement with FDAs expectations.
UHP has a proven product but this is not going to push them to the start of the line after setbacks.
Time for UHP regulatory consultant to do his job:
“On July 13 the company and its regulatory consultant met with the full FDA team”
“…and we conclude that the validation of certain elements of our manufacturing process are necessary to assemble a complete portfolio of information that the FDA can then use to complete its review our PMA application. “
Link to a PMA supplement completed last week for an established competitor. Every little change has to be documented and approved by FDA. Even for the big boys.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=N12159S094
Approval To Establish A New Slit And Cutting Room In The Ethicon LLC San Lorenzo, Puerto Rico Manufacturing Facility.
I agree, “mislead”applies more to the PRs. I suppose better wording in regards to FDA would be- don’t underestimate the level of scrutiny the PMA is exposed to. (Don’t cut corners)
Hemostyp is a superior product to Surgicel and under the right guidance it will be a Class 3 gauze.
But PMAs can die on the vine if not managed properly. They will then have to restart the process.
Again, this product will be Approved at some point. I would prefer if it was on this go around.
Positive post coming…I’m not sure why everyone is so shocked by this outcome. On May 24 2022 I wrote:
“I believe even those wearing the thickest of rose colored glasses will read the PR and deduce that UHP is not expecting to leave the meeting with the approval in hand.
Our hope needs to be that they are provided a specific list of hurdles remaining. With that, they can work towards jumping those hurdles in a timely manner.
And if all are crossed successfully approval should be granted on schedule I laid out in post 9247 on May 2nd. “
FDA has. Now provided exactly what I predicted we need in order to move forward in a positive direction.
Though this is not being called an official Approvable Letter DR5 and I had referenced before, it is the next best thing.
My advice is to throw away the timeline predictions and pray that management gets this right. I do believe it’s their last chance. Don’t try to mislead the FDA or your investors going forward. I believe (hope) they have finally realized this and are moving forward in a positive direction.
Rodman, When was the actual FDA walk through?
April 2022
“. The company notes that its manufacturing equipment remains in good operational condition and is on location at the premises of our FDA-approved contract manufacturing partner. The equipment is ready to become operational in anticipation of an FDA inspection and/or the need to produce HemoStyp material for commercial orders.”
BTW this PR came after my March call out. They must be reading my posts.
Hopefully they just need to prove the ability to produce the product.
Meaning, proof that they have sourced the appropriate raw materials and have an approved sterile manufacturing facility on contract.
For example, a manufacturer such has Strouse has already proven to FDA a that they can manufacture sterile bandages so the process would go much smoother with a reputable like Strouse.
Personally, I feel UHP needs to take as much time as it takes to get it right and then they will be approved.
There’s no more room for cutting corners on this submission.
“ their comments were very helpful and we conclude that the validation of certain elements of our manufacturing process are necessary to assemble a complete portfolio of information that the FDA can then use to complete its review our PMA application. We will work expeditiously with our manufacturing partner in the coming weeks to accomplish these remaining tasks.”
Hopefully 3 months for the paperwork portion. Then the review. Don’t rush it UHP. Just get the approval.
BB you’re new here, but you will soon learn there are no small hurdles when it comes to manufacturing.
As I’ve addressed previously, UHP moved manufacturing post human trials. Hence, they needed to prove they could make the identical product here, with equal raw materials in a factory meeting FDA standards.
UHP failed to disclose the move to FDA in a timely manner which meant the initial process for approval was on dated/inaccurate information.
Therefore, they we’re required to submit a major amendment ( as I’ve outlined and unfortunately been forced to debate here)
The amendment was filed poorly and incomplete by FDA standards which resulted in yet more wasted FDA time.
This PR proves my previous points, and clearly the FDA is saying “ get your manufacturing facts in order and we’ll get this thing APPROVED! But please stop screwing around. “
Note to all:
Stop doubting me.
March 24 2022
As I mentioned before, all delays are manufacturing related.
There is nothing the FDA can do until UHP can prove capable of producing hemostyp gauze in the new facility exactly as they used in the human trials.
As a result, until they get a line running at Strouse (or wherever they intend to make it now) the FDA can not complete the approval.
The only question the next PR needs to answer is when/where will this happen. Even a small sample run will suffice.
https://www.strouse.com/
UHP is not currently listed as a partner.
In hindsight they now realize they should have left manufacturing in China active until the PMA was complete and then moved it to the US and simply applied for a PMA supplement to get clearance for the move.
These are statements of fact.
You know what DR5, that’s a solid post.
The approvable letter is precisely what we’re after. As long as UHP has their ducks in a row and responds to the letter in a timely manner, we’re well on our way to PMA success.
Thank You.
Re Trigger Events. I laid this down in Dec 2020:
Wednesday, December 09, 2020 10:44:58 AM
Re: None
Post# of 9620 Go
Thom’s 11.5 million share vesting schedule:
The restricted stock unit awards vest upon performance and do not contain a conversion or exercise price. 5% of the RSU's vest upon FDA approval of the company's class III PMA, an additional 10% of the RSU's will vest upon the execution of each commercial distribution agreement for the marketing of its products up to a maximum of three such agreements and the balance will vest upon the company achieving $30 million in gross cumulative sales or a covered transaction as defined in the agreement.
A trigger event- like completing an acquisition of UEEC is the quickest route to his riches.
MoneyMach you are showing the ability to ask relevant questions.
On May 11th someone said:
“UEEC--LOL. When insiders BUY, so should you.”
It traded to 0.78 on the 12th.
It now sits. At 0.35.
CEO has had multiple sells since.
On May 12 another poster said…:
As everyone’s personal research has disclosed. The last insider buy on the Open Market was Oct 19 2021.
At this time Mr Thom bought on the Open Market at 0.95.
This Open Market trade was quite encouraging. However, the stock didn’t hold at 0.95, and started its steady decline into the 0.40s.
So, insider buys (especially on Open Market) are great, but aren’t always a sign that an investor should Buy right away.
Fair response B. I actually agree with you. However this has been acknowledged many times on the board. This stock has been heavily manipulated for years. The same techniques are used to drive it up and down.
Now, regarding my previous post, you should know that I must remain neutral while conducting a scientific survey. I will add b) and c) to your earlier standing.
More importantly,, you will need to tone down the attitude if you want to work at the bake sale. Stale bran muffins have no value.
Thanks for posing the question. It will return some very valuable insights I’m sure.
The bakery is now open.
I’m marking you down as an a) b) and c).
You’re correct. This is a lot of data for one person to control. I can assure you that I don’t take this responsibility lightly. My team is held to a very high standard.
I can see that all of this waiting is starting to stress people out.
Please be patient, a survey this scientific takes time. But in the end it will be worth it.
Great work thinking out side of the box Dark2. I had a good laugh. However, to uphold the integrity of this survey I can’t change it now. Besides, my team is already analyzing the data.
Thanks Lonetree, you just helped guide my future posts. When one improves, we all improve.
I’ll crunch the numbers later on.
Thank You Chrism. I’ll mark you down as e) all of the above.
Your participation is appreciated.
I’m doing a quick survey. Please take a moment to reply, as it’s the best way to improve.
Did todays posts contain too much:
a) math
b) logic
c) DD
d) hubris
e) all of the above
Thank You.
Hello kettleman, the best I can offer you as an explanation is a Mar 2021 quote from….you guessed it: Me.
“At least you’re specifying GAUZE market this time.
Meaning you must adjust your $5.8 Billion sales # as well.
So, 25% of a 900 Million. $225 Million in POTENTIAL sales.
I’m not sure they’ll get a $2.5 B offer for $225 M sales.
Last year J&J offered $400 Million for Tachosil patch which has $155 m in yearly sales.
Fell through, but a realistic example. Real DD matters.
It was a follow up to Feb 2021 DD post:
“… if you truly know the market you would understand that gauze makes up less than 15% of the market. The majority belongs to injectables, sponges, spays, powders and gels.
It’s hard to take over 25% of the entire market when startOmg from 0. Nevertheless, when at this time only 15% of the market is available.
Yes I am aware of the current PRs stating patents have been filed and RD continues on other hemostyp products. “
Here’s some optimism: Guessing you bough in May at 0.5 to 0.7.
Using your $2-$3 future buyout estimate (thanks for the realistic view btw,) you will enjoy up to a 500 % ROI.
That’s an incredible return for “all this “waiting.”
He was likely referring to these shares:
1)
Includes 200,000 shares of common stock to be sold by John Phillips, which were issued to Mr. Phillips in lieu of cash compensation for services rendered to the Company pursuant to the terms of the Philips Employment Agreement.
(2)
Includes 200,000 shares of common stock to be sold by John Gerhardt, which were issued to Mr. Gerhardt in lieu of cash compensation for services rendered to the Company pursuant to the terms of the Gerhardt Employment Agreement.
Good to hear from you Band Aid. However, I’m hesitant to respond as it typically leads to a firestorm of negativity. But apparently I have an axe to grind, so here goes:
I believe even those wearing the thickest of rose colored glasses will read the PR and deduce that UHP is not expecting to leave the meeting with the approval in hand.
Our hope needs to be that they are provided a specific list of hurdles remaining. With that, they can work towards jumping those hurdles in a timely manner.
And if all are crossed successfully approval should be granted on schedule I laid out in post 9247 on May 2nd.
As an aside, I am marginally concerned that UHP allowed their CE mark to expire without having it extended/renewed. CEs usually run 3 years and can be renewed without difficulty.
So either this was a paperwork oversight on UHPs end, or there is an issue with the manufacturing move.